Polymorphisms in drug transporter and metabolism genes associated with resistance to imatinib in chronic myeloid leukemia: A systematic review and meta analysis
Cargando...
Archivos
Fecha
2024
Título de la revista
ISSN de la revista
Título del volumen
Editor
Ediciones Universidad Simón Bolívar
MDPI
Facultad de Ciencias Básicas y Biomédicas
MDPI
Facultad de Ciencias Básicas y Biomédicas
Resumen
The aim of this study was to establish the relationship between different polymorphisms
in drug transporter and metabolizer genes and resistance to imatinib in chronic myeloid leukemia
(CML). For this purpose, an exhaustive search was carried out in the Scopus, Web of Science, and
PubMed databases using different combinations of keywords with different inclusion and exclusion
criteria. The meta-analysis included nine studies that met the established criteria. The results of the
study showed that the polymorphic variants AG and GG of CYP3A5*3 are associated with response
to treatment, presenting a significantly lower risk with resistance to imatinib. Likewise, the variants
T1236C and G2677T/A of the ABCB1 gene show a significant association with treatment efficacy. In
addition, the genetic polymorphism 1236T, homozygous CC of the MDR1 gene, significantly influences
the increased risk of cytogenetic relapse and the polymorphic variant 361G>A GA of the
SLCO1A2 gene significantly affects the complete molecular response.
Descripción
Palabras clave
Citación
Gómez, A.M.A.; Díaz-Mendoza, M.A.; Lemus, Y.B.; León-Mejía, G.; Benitez, M.L.R. Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Sci. Pharm. 2024, 92, 2. https://doi.org/10.3390/ scipharm92010002
